Effects and safety of ferric citrate hydrate in patients with receiving hemodialysis.
Not Applicable
- Conditions
- Chronic hemodialysis patients
- Registration Number
- JPRN-UMIN000028669
- Lead Sponsor
- Tomei-Atsugi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
AST,ALT over100 IU/L. Allergy to riona. Pregnant or possible pregnancy. Inappropriate patients regarded by doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ferric citrate hydrate's efficacy in managing iron overload and anemia in hemodialysis patients?
How does ferric citrate hydrate compare to IV iron or ESAs in improving hemoglobin levels and reducing transfusion needs in chronic hemodialysis patients?
Which biomarkers correlate with treatment response to ferric citrate hydrate in patients with end-stage renal disease undergoing hemodialysis?
What are the potential adverse events of ferric citrate hydrate, and how do they compare to other phosphate binders like sevelamer or lanthanum carbonate?
Are there synergistic effects when combining ferric citrate hydrate with erythropoiesis-stimulating agents in anemia management for hemodialysis patients?